Cancer Biology & Medicine

►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".

 

►►Very important notification on publication fee

Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.


Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

Author Benefits

● Easy submission via online system

● Efficient and professional peer review

● Rapid pre-print online publication

● No charge for publication and open access

● International visibility-All full texts are free in PubMed Central

 

Announcements

 

Greetings from Cancer Biology & Medicine

 
 
Posted: 2020-01-24
 

Publication of the 4th issue in 2019

 

In the 4th issue, we recommend several reviews on immunotherapy referring to advances in NK cell-based cellular immunotherapy, tumor pseudoprogression after immunotherapy, and low-frequency HIFU induced cancer immunotherapy, respectively. Research articles of this field contain new technologies on photothermal/photodynamic therapy and immunotherapy, and study of PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients.

Besides, a guideline and its interpretation from China Anti-Cancer Association and National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) indicate the breast cancer screening for Chinese women. They provide more information and practical methodologies for current breast cancer screening in China. Other papers on cancer epidemiology, drug resistance, novel mechanisms of cancer progression, and so on can be also helpful to clinicians and researchers.

We hope the content of this issue will greatly benefit your research and clinical practice. Thank you for your attention and welcome to submit your work to Cancer Biology & Medicine.

 


 
Posted: 2019-11-15
 
More Announcements...

Vol 16, No 4: November 2019

Table of Contents

Editorial

Capture a live-photo of tumor infiltrating T cell landscape at single cell resolution PDF HTML
Xin Dong, Ruidong Xue 619-622
Clinical proteomics: a driving force for cancer therapeutic target discovery and precision medicine PDF HTML
Hao Wang, Na Jiang, Yali Zhang, et al 623-629

Review

The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer? PDF HTML
Yulu Zhou, Yong Shen, Cong Chen, et al. 630-646
Technical advances in NK cell-based cellular immunotherapy PDF HTML
Fang Fang, Wei Wang, Minhua Chen, et al. 647-654
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy PDF HTML
Wenxiao Jia, Qianqian Gao, Anqin Han, et al 655-670
Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism PDF HTML
Tong Wang, Zhiyong Wang, Ruifang Niu, et al. 671-687
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview PDF HTML
Francisco Quiñonero, Cristina Mesas, Kevin Doello, et al. 688-699
Tobacco, air pollution, environmental carcinogenesis, and thoughts on conquering strategies of lung cancer PDF HTML
Guangbiao Zhou 700-713
Low-frequency HIFU induced cancer immunotherapy: tempting challenges and potential opportunities PDF HTML
Guilian Shi, Mingchuan Zhong, Fuli Ye, et al. 714-728

Original Article

PADI3 induces cell cycle arrest via the Sirt2/AKT/p21 pathway and acts as a tumor suppressor gene in colon cancer PDF HTML
Xiaotian Chang, Zhengbin Chai, Jiaorui Zou, et al. 729-742
Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma PDF HTML
Meifang Xu, Fei Wang, Hong Chen, et al. 743-755
Human natural killer cells for targeting delivery of gold nanostars and bimodal imaging directed photothermal/photodynamic therapy and immunotherapy PDF HTML
Bin Liu, Wen Cao, Jin Cheng, et al. 756-770
ILF2 cooperates with E2F1 to maintain mitochondrial homeostasis and promote small cell lung cancer progression PDF HTML
Meng Zhao, Yahui Liu, Jiao Chang, et al. 771-783
Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis PDF HTML
Yingbin Xie, Yanli Tan, Chao Yang, et al. 784-796
Nomogram based on albumin-bilirubin grade to predict outcome of the patients with hepatitis C virus-related hepatocellular carcinoma after microwave ablation PDF HTML
Chao An, Xin Li, Xiaoling Yu, et al. 797-810
The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series PDF HTML
Jianghua Wu, Wei Sun, Haiyue Wang, et al. 811-821

Guideline

Breast cancer screening guideline for Chinese women PDF HTML
China Anti-Cancer Association, National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) 822-824

Guideline Interpretation

Interpretation of breast cancer screening guideline for Chinese women PDF HTML
Yubei Huang, Zhongsheng Tong, Kexin Chen, et al. 825-835

Erratum

Erratum to Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer PDF HTML
Yuxiang Wang, Xian Li, Xueling Liu, et al. 836


OUR FRIENDS